Want to see SE:DVYSR full AI Analyst Report?
Top Page
Devyser Diagnostics AB
(DVYSR)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr64.00
▲(8.66% Upside)
Action:Reiterated
Date:07/21/26
The score is anchored by improving financial performance (return to profitability and low leverage), but is held back by weak price momentum (below key moving averages with bearish MACD) and a high P/E multiple with no dividend yield support.
Positive Factors
Profitability inflection
The company has moved to TTM profitability with double‑digit operating and strong EBITDA margins, signaling structural operating leverage. Sustained profitability provides cash for reinvestment in commercial scale, R&D and regulatory filings, reducing dependence on financing.
Negative Factors
Weak revenue trend
Top‑line contraction suggests current earnings improvement is driven more by cost and margin actions than sustainable demand growth. For diagnostics, recurring volume and placements matter; without durable revenue expansion, maintaining margins and improving returns is more difficult long term.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability inflection
The company has moved to TTM profitability with double‑digit operating and strong EBITDA margins, signaling structural operating leverage. Sustained profitability provides cash for reinvestment in commercial scale, R&D and regulatory filings, reducing dependence on financing.
Read all positive factors
Devyser Diagnostics AB (DVYSR) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.01B
Dividend YieldN/A
Average Volume (3M)13.82K
Price to Earnings (P/E)65.2
Beta (1Y)0.55
Revenue Growth6.51%
EPS GrowthN/A
CountrySE
Employees110
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.92
Shares Outstanding16,889,807
10 Day Avg. Volume13,007
30 Day Avg. Volume13,825
Financial Highlights & Ratios
PEG Ratio2.59
Price to Book (P/B)5.35
Price to Sales (P/S)7.56
P/FCF Ratio282.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.6
Revenue Forecast (FY)kr245.80M
Devyser Diagnostics AB Business Overview & Revenue Model
Company Description
Headquartered in Hägersten, Sweden, and established in 2004, Devyser Diagnostics AB (publ) specializes in the development, manufacturing, and global sale of advanced diagnostic kits and solutions for DNA testing. The company's innovative products ...
How the Company Makes Money
Devyser Diagnostics makes money primarily by selling molecular diagnostic products (IVD kits/assays) to clinical laboratories and similar customers that perform genetic testing. Revenue is generated when labs purchase these assays for routine test...
Devyser Diagnostics AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.40M | 250.50M | 216.90M | 169.30M | 126.61M | 93.48M |
| Gross Profit | 195.80M | 201.90M | 172.70M | 148.10M | 105.77M | 74.66M |
| EBITDA | 53.50M | 37.70M | -31.20M | -43.80M | -46.02M | -18.05M |
| Net Income | 15.30M | -8.40M | -61.50M | -53.60M | -45.95M | -20.73M |
Balance Sheet | ||||||
| Total Assets | 493.10M | 469.70M | 473.80M | 510.10M | 500.63M | 456.87M |
| Cash, Cash Equivalents and Short-Term Investments | 81.00M | 77.50M | 144.50M | 262.90M | 363.60M | 377.64M |
| Total Debt | 45.80M | 51.90M | 59.10M | 74.80M | 21.20M | 12.96M |
| Total Liabilities | 112.10M | 115.40M | 124.80M | 125.00M | 69.19M | 40.18M |
| Stockholders Equity | 381.00M | 354.30M | 349.10M | 385.10M | 431.44M | 416.68M |
Cash Flow | ||||||
| Free Cash Flow | 20.50M | 6.70M | -123.70M | -101.70M | -66.30M | -25.28M |
| Operating Cash Flow | 36.00M | 8.20M | -46.80M | -69.70M | -40.50M | -16.48M |
| Investing Cash Flow | -58.50M | -70.70M | -76.90M | -32.00M | -23.86M | -10.32M |
| Financing Cash Flow | 3.10M | -2.80M | 7.80M | -200.00K | 48.94M | 395.93M |
Devyser Diagnostics AB Technical Analysis
Negative
58.90
Price Trends
62.90
Negative
77.14
Negative
87.61
Negative
Market Momentum
-1.54
Negative
42.31
Neutral
62.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DVYSR, the sentiment is Negative. The current price of 58.9 is below the 20-day moving average (MA) of 60.23, below the 50-day MA of 62.90, and below the 200-day MA of 87.61, indicating a bearish trend. The MACD of -1.54 indicates Negative momentum. The RSI at 42.31 is Neutral, neither overbought nor oversold. The STOCH value of 62.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:DVYSR.
Devyser Diagnostics AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | kr1.01B | 65.22 | ― | ― | 6.51% | ― | |
49 Neutral | kr423.36M | -32.18 | ― | ― | 54.37% | 52.22% | |
48 Neutral | kr112.74M | -0.89 | -279.07% | ― | 31.66% | 79.68% | |
47 Neutral | kr118.05M | -29.48 | -58.52% | 1.06% | -10.60% | 98.81% | |
42 Neutral | kr80.97M | -0.44 | -229.18% | ― | 143.94% | 70.95% | |
30 Underperform | kr189.17M | -1.15 | -303.61% | ― | 51.21% | 42.24% |
* General Sector Average
SE:DVYSR
Devyser Diagnostics AB
60.00
-85.00
-58.62%
SE:BOUL
Boule Diagnostics AB
3.06
-2.96
-49.17%
SE:IMMNOV
Immunovia AB
0.15
-0.35
-69.82%
SE:SCIB
SciBase Holding AB
18.30
-9.20
-33.45%
SE:PROGEN
Prostatype Genomics AB
0.18
-0.04
-18.98%
SE:CLBIO
Corline Biomedical AB
15.85
1.25
8.56%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.